Plasma HIV RNA level is associated with neurocognitive function among HIV-1-infected patients in Nigeria
- 56 Downloads
Plasma HIV RNA level has been shown to correlate with HIV disease progression, morbidity, and mortality. We examined the association between levels of plasma HIV RNA and cognitive function among patients in Nigeria. A total of 179 HIV-1-infected participants with available plasma HIV RNA results and followed longitudinally for up to 2 years were included in this study. Blood samples from participants were used for the measurement of plasma HIV RNA and CD4+ T cell count. Utilizing demographic and practice effect-adjusted T scores obtained from a seven-domain neuropsychological test battery, cognitive status was determined by the global deficit score (GDS) approach, with a GDS ≥ 0.5 indicating cognitive impairment. In a longitudinal multivariable linear regression analysis, adjusting for CD4 cell count, Beck’s Depression Score, age, gender, years of education, and antiretroviral treatment status, global T scores decreased by 0.35 per log10 increase in plasma HIV RNA [p = 0.033]. Adjusting for the same variables in a multivariable logistic regression, the odds of neurocognitive impairment were 28% higher per log10 increase in plasma HIV RNA (OR 1.28 [95% CI 1.08, 1.51]; p = 0.005). There were statistically significant associations for the speed of information processing, executive, and verbal fluency domains in both linear and logistic regression analyses. We found a significant association between plasma HIV RNA levels and cognitive function in both baseline (cross-sectional) and longitudinal analyses. However, the latter was significantly attenuated due to weak association among antiretroviral-treated individuals.
KeywordsPlasma HIV RNA Cognitive function Nigeria
This work was supported by the National Institutes of Health grant no. R01 MH086356 (to William A. Blattner and Walter Royal, III) and by the National Institutes of Health Fogarty/AIDS International Training and Research Program grant no. 2D43TW001041-14 (training support to Jibreel Jumare).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
This work was presented in part at the 19th Annual International Meeting of the Institute of Human Virology, 23rd-26th October 2017, Baltimore, Maryland, USA (Abstract P-D6).
- Akolo C, Royal W III, Cherner M, Okwuasaba K, Eyzaguirre L, Adebiyi R, Umlauf A, Hendrix T, Johnson J, Abimiku A e, Blattner W (2014) Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria. J Neurovirol 20(4):380–387CrossRefPubMedPubMedCentralGoogle Scholar
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799CrossRefPubMedPubMedCentralGoogle Scholar
- Beck AT, Steer RA ,Brown GK (1996) Beck Depression Inventory San Antonio, TX, Psychological CorporationGoogle Scholar
- Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Ellis RJ, Atkinson JH, Grant I, Heaton RK (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26(6):894–908CrossRefPubMedGoogle Scholar
- Camlin CS, Seeley J, Viljoen L, Vernooij E, Simwinga M, Reynolds L, Reis R, Plank R, Orne-Gliemann J, McGrath N, Larmarange J, Hoddinott G, Getahun M, Charlebois ED, Bond V (2016) Strengthening universal HIV ‘test-and-treat’ approaches with social science research. AIDS (London, England) 30(6):969–970CrossRefGoogle Scholar
- Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA (1997) Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 42(5):679–688CrossRefPubMedGoogle Scholar
- Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan J, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I (2002) Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus rna. Arch Neurol 59(6):923–928CrossRefPubMedGoogle Scholar
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23):2087–2096CrossRefPubMedPubMedCentralGoogle Scholar
- Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3–16CrossRefPubMedGoogle Scholar
- Jumare J, Sunshine S, Ahmed H, El-Kamary SS, Magder L, Hungerford L, Burdo T, Eyzaguirre LM, Umlauf A, Cherner M, Abimiku A, Charurat M, Li JZ, Blattner WA, Royal W 3rd (2017) Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. J Neurovirol 27(10):017–0520Google Scholar
- Marcotte TD, Deutsch R, McCutchan J, Moore DJ, Letendre S, Ellis RJ, Wallace MR, Heaton RK, Grant I, San Diego HIV Neurobehavioral Research Center (HNRC) Group (2003) Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 60(10):1406–1412CrossRefPubMedGoogle Scholar
- Price RW, Spudich S (2008) Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 15(197):533419Google Scholar
- Royal W 3rd, Cherner M, Burdo TH, Umlauf A, Letendre SL, Jumare J, Abimiku A, Alabi P, Alkali N, Bwala S, Okwuasaba K, Eyzaguirre LM, Akolo C, Guo M, Williams KC, Blattner WA (2016) Associations between cognition, gender and monocyte activation among HIV infected individuals in Nigeria. PLoS One 11(2):e0147182CrossRefPubMedPubMedCentralGoogle Scholar
- Stankoff B, Calvez V, Suarez S, Bossi P, Rosenblum O, Conquy L, Turell E, Dubard T, Coutellier A, Baril L, Bricaire F, Lacomblez L, Lubetzki C (1999) Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. Eur J Neurol 6(6):669–675CrossRefPubMedGoogle Scholar